ELTX Stock Forecast & Price Target

Elicio Therapeutics is well positioned because its AMP platform has shown clear clinical and mechanistic validation, with 84% of 25 Phase 1 patients mounting mKRAS-specific T cells, 24% clearing ctDNA, and median RFS of 16.33 months versus historical MRD-positive PDAC benchmarks of 5.0 to 6.4 months. The outlook is further strengthened by the upgraded ELI-002 7P formulation, which achieved a 100% T cell response rate in Phase 1a, produced a median 113.3x T cell fold-change at the Phase 2 dose, and showed a clean safety profile with no dose-limiting toxicities or treatment-related deaths. Confidence also rises from the Phase 2 AMPLIFY-7P results, which reduced development risk enough to lift the probability of approval to 65% from 50% and raised estimated peak market penetration to 50% from 20%, while the off-the-shelf, lymph node-targeted design supports broad commercial scalability across PDAC and CRC.

Elicio Therapeutics is fundamentally challenged by a highly uncertain single-asset story, where even the core ELI-002 7P program is only assigned a 65% probability of regulatory approval and remains exposed to failures in Phase 2 efficacy, Phase 3 execution, and regulatory review. While the Phase 1a data showed a dose response, with 71% biomarker decline at 4.9 mg versus 40% at 1.4 mg and 70% antigen spreading across 10 patients, the small sample size, maturing dataset, and incomplete booster dosing limit confidence in durability and translation. Financially, the company still faces near- to medium-term dilution risk and may need additional capital before profitability, even with a cash runway extending through 4Q26, while commercialization is also constrained by IP dependencies and the possibility that MIT-controlled patents or pending applications fail to protect key assets.